Investment Thesis

, while a significant drop below $45 may present a more attractive entry point.

Competitive Moat

characterized by strong intangible assets, specifically its extensive intellectual property portfolio and regulatory approvals across diverse medical specialties. The company's scale allows for significant economies, driving down costs while enhancing R&D capabilities. This advantage is durable over the next 5-10 years, although competitive threats from agile startups introducing disruptive technologies and established players such as Medtronic could pose challenges to BSX's market share.

Growth Engine

Future revenue growth for Boston Scientific is anchored in its vast total addressable market (TAM), estimated to exceed $50 billion across its key segments, including MedSurg, Rhythm and Neuro, and Cardiovascular. The company is well-positioned to benefit from an aging global population, increasing chronic disease prevalence, and expanding healthcare access in emerging markets. While BSX has historically pursued organic growth through innovative product launches, it remains open to acquisition-driven growth, potentially bolstering its portfolio. Currently, BSX is gaining market share, particularly in its cardiovascular and rhythm management divisions, driven by the introduction of next-generation devices.